Sunovion Pharmaceuticals

What Sunovion Pharmaceuticals does

Sunovion Pharmaceuticals Inc., founded in 1984 and headquartered in Marlborough, Massachusetts, is a U.S.-based specialty pharmaceutical company that discovers, develops, and commercializes therapeutic products primarily for patients with central nervous system (CNS) and respiratory disorders. Through its parent company Sumitomo Pharma America (SMPA), a U.S. subsidiary of Japanese pharmaceutical group Sumitomo Pharma Co., Ltd., the company maintains a diversified pipeline spanning oncology, women's health, urology, rare disease, CNS, and cell & gene therapies. Sunovion's product portfolio includes FDA-approved branded specialty pharmaceuticals (notably in CNS and respiratory), and the company has historically expanded through acquisitions — most notably Elevation Pharmaceuticals in 2012 ($430M, respiratory) and Cynapsus Therapeutics in 2016 ($624M, Parkinson's/CNS). The firm employs 5,001–10,000 people and operates as a privately held subsidiary, with no separately disclosed financials.

Sunovion generates revenue through standard pharmaceutical commercialization: branded prescription drugs sold via hospital pharmacies, retail pharmacies, and online pharmacies globally. Its go-to-market leverages the regulatory approvals and clinical evidence base of its branded products, distributed through traditional pharma channels rather than direct-to-consumer or technology-platform models. Pricing is not publicly disclosed, consistent with B2B/B2B2C pharmaceutical pricing where reimbursement is negotiated through insurers, pharmacy benefit managers (PBMs), and government payers. Recent strategic activity includes a 2023 partnership with Bod Science Pty Ltd to advance an investigational insomnia therapy, signaling continued investment in CNS-adjacent therapeutic areas. No AI/ML capabilities, proprietary technology platforms, or software products are disclosed in the available source material — the company's competitive positioning rests on regulatory approvals, clinical data, capital backing from its Japanese parent, and a diversified therapeutic pipeline.

Name

Sunovion Pharmaceuticals

Website

https://sunovion.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Sunovion Pharmaceuticals is a U.S.-based specialty pharmaceutical subsidiary of Sumitomo Pharma that discovers, develops, and commercializes branded therapeutics for CNS, respiratory, oncology, women's health, urology, rare disease, and cell & gene therapy patients.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• CNS therapeutics
• Respiratory pharmaceuticals
• Specialty drug development
• Rare disease treatments
• Cell and gene therapy

Headquarters

HQ city

Marlborough

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Distribution channels3 records

Marketing channels3 records

Core offering

Sunovion Pharmaceuticals discovers, develops, and commercializes therapeutic products focused on central nervous system (CNS) disorders and respiratory diseases. Through its parent Sumitomo Pharma America, the business extends across oncology, women's health, urology, rare disease, and cell and gene therapies, with active preclinical and clinical programs addressing unmet medical needs.

Product overview

Sumitomo Pharma America (SMPA), parent company of Sunovion Pharmaceuticals, operates a diversified pharmaceutical business focused on drug discovery, development, and commercialization across multiple therapeutic areas including oncology, women's health, urology, rare disease, CNS (central nervous system), and cell & gene therapies. The company maintains a pipeline of preclinical and clinical programs targeting areas of unique and unmet medical need. No specific Sunovion-branded products or named offerings are detailed in the available source material.

Differentiator

Problem solved

Functional benefit

Products and services

• CNS therapeutics portfolio

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Bod Science Pty LtdminorStrategic or Co-development Partner · 1 October 2023Dutch company dsm-firmenich N.V. partnered with Australia's Bod Science Pty Ltd to advance an investigational insomnia therapy using GMP-grade pharmaceutical products to support clinical trials and regulatory approval.

Scale indicators6 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Lundbeck: Lundbeck is a global specialty pharmaceutical company dedicated to CNS disorders, including depression, schizophrenia, Parkinson's disease, and rare neurological conditions. It is a direct competitor to Sunovion's CNS franchise and operates at comparable scale.
• Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharmaceutical company with a strong CNS franchise (sleep, epilepsy, psychiatry) and recent oncology expansion. It is directly comparable to Sunovion in therapeutic area focus, mid-sized specialty positioning, and US commercialization model.
• Acadia Pharmaceuticals: Acadia Pharmaceuticals is a specialty CNS company focused on neurological disorders, including Parkinson's disease psychosis (Nuplazid) and Rett syndrome. It directly competes with Sunovion in CNS specialty therapeutics at a similar scale.
• Theravance Biopharma: Theravance is a mid-sized specialty pharmaceutical company with a focus on respiratory therapeutics (including Yupelri for COPD). It is directly comparable to Sunovion's respiratory franchise and shares the mid-cap specialty pharma model.
• Intra-Cellular Therapies: Intra-Cellular Therapies develops and commercializes CNS therapeutics, most notably Caplyta for schizophrenia and bipolar depression. It is a comparable specialty CNS pharmaceutical company with similar scale and commercial focus to Sunovion.
• Supernus Pharmaceuticals: Supernus is a US specialty pharma focused on CNS disorders, particularly epilepsy, ADHD, and Parkinson's disease. It directly competes with Sunovion's CNS franchise and shares a similar mid-cap specialty pharma business model.

Broad incumbents

• Takeda Pharmaceutical Company: Takeda is a large Japanese-headquartered pharmaceutical company with substantial US operations in CNS, gastroenterology, and rare diseases. Comparable to Sunovion/Sumitomo as another Japanese pharma parent with US specialty pharmaceutical footprint.
• Otsuka Pharmaceutical Development & Commercialization: Otsuka is a major Japanese pharmaceutical company's US operation with significant CNS presence (Abilify, Abilify Asimtufii). Comparable to Sunovion as a Japanese pharma US subsidiary with a strong CNS specialty focus and similar cross-border parent-subsidiary structure.
• Eisai Inc. Eisai is a Japanese pharmaceutical company's US subsidiary with established CNS (Alzheimer's, insomnia) and oncology franchises. It shares Sunovion's positioning as a Japan-headquartered pharma's US CNS-focused subsidiary with diversified therapeutic area ambitions.
• Astellas Pharma US: Astellas is a Japanese pharmaceutical company's US subsidiary with focus areas including oncology, women's health, and rare disease. It is comparable to Sunovion as a Japan-headquartered pharma's US specialty operation with a diversified therapeutic portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/sunovion
• Facebookfacebook.com/sunovion
• LinkedInlinkedin.com/company/sunovion-pharmaceuticals-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sunovion Pharmaceuticals